iShares U.S. Pharmaceuticals ETF (IHE)

NYSEARCA: IHE · IEX Real-Time Price · USD
-1.15 (-0.61%)
Aug 17, 2022 4:00 PM EDT - Market closed
Assets $447.17M
NAV $190.29
Expense Ratio 0.42%
PE Ratio 16.79
Shares Out 2.35M
Dividend (ttm) $3.13
Dividend Yield 1.66%
Ex-Dividend Date Jun 9, 2022
1-Year Return -4.14%
Volume 4,270
Open 188.64
Previous Close 189.82
Day's Range 188.34 - 189.75
52-Week Low 176.96
52-Week High 202.77
Beta 0.76
Holdings 45
Inception Date May 1, 2006

About IHE

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Asset Class Equity
Sector Biotech
Region North America
Issuer BlackRock iShares
Stock Exchange NYSEARCA
Ticker Symbol IHE
Index Tracked Dow Jones U.S. Select Pharmaceuticals Index

Top 10 Holdings

76.95% of assets
Name Symbol Weight
Johnson & Johnson JNJ 21.53%
Pfizer PFE 19.47%
Royalty Pharma RPRX 4.87%
Zoetis ZTS 4.68%
Merck & Co. MRK 4.65%
Eli Lilly and Company LLY 4.60%
Catalent CTLT 4.60%
Bristol-Myers Squibb Company BMY 4.50%
Viatris VTRS 4.31%
Jazz Pharmaceuticals JAZZ 3.75%
View More Holdings


Ex-Dividend Amount Pay Date
Jun 9, 2022 $0.71711 Jun 15, 2022
Mar 24, 2022 $0.79357 Mar 30, 2022
Dec 13, 2021 $0.7898 Dec 17, 2021
Sep 24, 2021 $0.832 Sep 30, 2021
Jun 10, 2021 $0.72063 Jun 16, 2021
Mar 25, 2021 $0.63484 Mar 31, 2021
Full Dividend History


JNJ Beats on Q2 Earnings, Cuts View: ETFs in Focus

Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.

Other symbols: IEIHIYHVHTXLV

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Sector ETF report for IHE

2 ETFs to Watch for Outsized Volume on Short-Term Treasuries & Healthcare

BIL and IHE both ETFs had traded in an outsized volume yesterday.

Other symbols: BIL

Pharma ETFs in Focus Post Q1 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: FTXHPJPPPHXPH

Worried About the Stock Market? Here Are 2 Safe Investments to Buy and Hold for Decades

These ETFs can balance stability and long-term growth.

Other symbols: MOAT

Solid Q4 Earnings Fail to Impress Pharma ETFs

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Other symbols: FTXHPJPPPHXPH

Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit

Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.

Other symbols: BBHUSOXLB

VIX and Biotech ETFs Invigorated Amid Pfizer COVID Pill News

Just when it seemed like the Omicron coronavirus variant might overshadow the traditional Santa Claus Rally, and stocks might be due for a deeper sell-off, equities gained momentum, bouncing for a secon...

Other symbols: SVXYVIXY

Top ETF Stories of November

The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.


ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus

The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Other symbols: FTXHPJPPPHXPH

Travel and Leisure ETFs Surge Amid Positive Jobs Data

Travel and leisure stocks and ETFs are making major moves on Friday, following a better-than-expected  October jobs report, and a fresh development in the coronavirus battle boosting enthusiasm for the ...

Other symbols: PEG

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.


Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: FTXHPJPPPHXPH

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Other symbols: FXHIEIHPJPPPH

5 Sector ETFs That Survived Last Week's Turmoil

We have highlighted five sector ETFs that performed well last week and survived the broad market rout.

Other symbols: BUGPSCCRING

Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause

Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...

Other symbols: BBHFHLCIEIH

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols: FDLFTXHIEIH

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols: FTXHPJPPPHXPH

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols: FTXHPJPPPHXPH

Best Pharmaceutical ETFs for Q1 2021

The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.

Other symbols: KUREXPH

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.


Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols: FTXHPJPPPHXPH

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Other symbols: FTXHPJPPPHXPH